Data regarding the patients’ demographic characteristics, comorbidities, and clinical findings were recorded using a questionnaire. All the patients underwent upper gastrointestinal (GI) endoscopy with a small, flexible Olympus (Melville, NY) GIF-N30 endoscope by four pediatric gastroenterologists in the Pediatric Gastroenterology Department of our center, and the findings were recorded in the questionnaire. The patients received Midazolam

(1mg/kg) intravenously several minutes before endoscopy as a sedative agent. Several mucosal biopsies were taken under direct visualization of the mucosa and the Inhibitors,research,lifescience,medical vasculature. Phosphate-buffered formalin was used for fixing the specimens and biopsies. Paraffin-embedded Inhibitors,research,lifescience,medical specimens were sectioned in 5-6 µm slices and were further stained with hematoxylin and eosin according to the standard laboratory methods. All the

slides were reviewed by a pathologist, and the results were recorded in the questionnaire. The criteria for reflux esophagitis were comprised of basal zone hyperplasia, elongated stromal papillae, and vascular ingrowths. The drugs consumed by the patients were Inhibitors,research,lifescience,medical further categorized as those being unrelated to esophagitis, those being responsible for inducing esophagitis, and those being effective in the treatment of esophagitis. NSAIDs, Prednisolone, Mycophenolate Mofetil (CellCept), Cyclosporine, Acyclovir, Metronidazole, Meropenem, Cyclophosphamide, Methotrexate, Warfarin, Ciprofloxacin, Erythromycin, Co-trimoxazole, Fluconazole, Mesalamine, and Tacrolimus were considered to be responsible for inducing esophagitis, whereas Omeprazole, Inhibitors,research,lifescience,medical Pantoprazole, Metoclopramide, Ondansetron, Ranitidine, Cimetidine, aluminium-magnesium, and Motilium were considered as effective agents in the treatment of esophagitis. The data were prospectively entered into a computer database, and were further analyzed by SPSS software, version 14.0 (SPSS Inc., Chicago, Illinois, USA). The data are reported as mean±SD or proportions. Results We studied 125 children with pathology-confirmed esophagitis. The study population consisted of 61

(48.8%) girls and 64 (51.2%) boys at a mean age of Dacomitinib 6.6±5.5 years. Inhibitors,research,lifescience,medical The demographic and clinical characteristics of the patients are summarized in table 1. Table 1 Demographic and clinical characteristics of 125 pediatric patients with esophagitis Repeated vomiting was the prominent symptom in our selleck chem Regorafenib series, which was it being reported by 75 (60%) patients, followed by fever in 35 (28%) and Brefeldin failure to thrive in 24 (19.2%). Most of the patients (60%) were more than 2 years of age and, thus, consumed a large variety of food. However, 16 (12.7%) patients were breastfed with a dairy elimination diet, while 14 (11.2%) were breastfed. The drugs being consumed by 107 (85.6%) patients were found to be responsible for inducing esophagitis, whereas in the others (14.4%), the drugs were unrelated to the disease. Liver transplantation (44.9%) and thrombocytopenia (23.